ArticleBMC medical imaging2025
HistoNeXt: dual-mechanism feature pyramid network for cell nuclear segmentation and classification.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ClinSegNet: Towards Reliable and Enhanced Histopathology Screening.Bioengineering (Basel, Switzerland) · 2025Article
- From Pixels to Precision-A Dual-Stream Deep Network for Pathological Nuclei Segmentation.Bioengineering (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop an end-to-end convolutional neural network model for analyzing hematoxylin and eosin(H&E)-stained histological images, enhancing the performance and efficiency of nuclear segmentation and classification within the digital pathology workflow.
methodsWe propose a dual-mechanism feature pyramid fusion technique that integrates nuclear segmentation and classification tasks to construct the HistoNeXt network model. HistoNeXt utilizes an encoder-decoder architecture, where the encoder, based on the advanced ConvNeXt convolutional framework, efficiently and accurately extracts multi-level abstract features from tissue images. These features are subsequently shared with the decoder. The decoder employs a dual-mechanism architecture: The first branch of the mechanism splits into two parallel paths for nuclear segmentation, producing nuclear pixel (NP) and horizontal and vertical distance (HV) predictions, while the second mechanism branch focuses on type prediction (TP). The NP and HV branches leverage densely connected blocks to facilitate layer-by-layer feature transmission and reuse, while the TP branch employs channel attention to adaptively focus on critical features. Comprehensive data augmentation including morphology-preserving geometric transformations and adaptive H&E channel adjustments was applied. To address class imbalance, type-aware sampling was applied. The model was evaluated on public tissue image datasets including CONSEP, PanNuke, CPM17, and KUMAR. The performance in nuclear segmentation was evaluated using the Dice Similarity Coefficient (DICE), the Aggregated Jaccard Index (AJI) and Panoptic Quality (PQ), and the classification performance was evaluated using F1 scores and category-specific F1 scores. In addition, computational complexity, measured in Giga Floating Point Operations Per Second (GFLOPS), was used as an indicator of resource consumption.
resultsHistoNeXt demonstrated competitive performance across multiple datasets: achieving a DICE score of 0.874, an AJI of 0.722, and a PQ of 0.689 on the CPM17 dataset; a DICE score of 0.826, an AJI of 0.625, and a PQ of 0.565 on KUMAR; and performance comparable to Transformer-based models, such as CellViT-SAM-H, on PanNuke, with a binary PQ of 0.6794, a multi-class PQ of 0.4940, and an overall F1 score of 0.82. On the CONSEP dataset, it achieved a DICE score of 0.843, an AJI of 0.592, a PQ of 0.532, and an overall classification F1 score of 0.773. Specific F1 scores for various cell types were as follows: 0.653 for malignant or dysplastic epithelial cells, 0.516 for normal epithelial cells, 0.659 for inflammatory cells, and 0.587 for spindle cells. The tiny model's complexity was 33.7 GFLOPS.
conclusionBy integrating novel convolutional technology and employing a pyramid fusion of dual-mechanism characteristics, HistoNeXt enhances both the precision and efficiency of nuclear segmentation and classification. Its low computational complexity makes the model well suited for local deployment in resource-constrained environments, thereby supporting a broad spectrum of clinical and research applications. This represents a significant advance in the application of convolutional neural networks in digital pathology analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.